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the era of targeted agents
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however, the term “cytokine” has been used to refer to 
the immunomodulating agents such as the interleukins 
(ils) and interferons (i n f s), interferon alfa (i n f α) and 
il-2 being the most evaluated cytokine agents.
2.  DISCUSSION
2.1  Interferon
Interferons are naturally occurring glycoproteins 
that have strong antiviral activity and the ability 
to modulate immune response and cell prolifera-
tion. The i n fs come in three subtypes: i n fα, i n fβ, 
and i n f γ 3. The antitumour activity of i n f is medi-
ated by various mechanisms—immunomodulation, 
antiproliferative activity, inhibition of angiogenesis, 
regulation of differentiation, interaction with growth 
factors, and modulation of gene expression, among 
others 4. The most extensively studied is i n fα, which 
has shown efficacy in r c c . Studies evaluating i n f γ 
have been negative.
In a Cochrane meta-analysis, treatment with 
i n f α was compared with treatment with a non-i n f α 
control 5,6. The pooled results of four randomized 
control trials (r c ts) showed that i n f α was associated 
with greater remission rates [partial (p r) and com-
plete (c r ) responses] as compared with controls 
(medroxyprogesterone acetate or vinblastine). The 
pooled response rates were 12.5% for i n f α and 1.5% 
for controls, with a pooled odds ratio (o r ) of 7.61 
[95% confidence interval (c i ): 3.02 to 19.2]. Treat-
ment with i n f α was associated with reduced 1-year 
mortality (o r : 0.56; 95% c i : 0.40 to 0.77). A subgroup 
analysis that compared studies using the recombinant 
subtypes i n f α2a and i n f α2b showed no difference 
between the two subtypes in either objective response 
or 1-year survival.
A meta-analysis by Wirth 7 of 1042 patients found 
that the overall proportion of responses (c r s and p rs) 
to i n f α was 12%. The c r s were rare. In patients with 
prior nephrectomy and in those with lung metastases, 
the proportion of objective responses was as high as 
44%. The average time from the start of treatment to 
an objective response was about 3–4 months. Metastases 
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1.  INTRODUCTION
Before the advent of the new anti-angiogenic agents, 
cytokines were considered the mainstay of treatment 
for locally advanced or metastatic renal cell carci-
noma (r c c ) because of a lack of improved survival 
with either chemotherapy 1 or hormonal therapy alone. 
Spontaneous tumour regressions and the presence of 
an antitumour immune response in patients with r c c  
prompted the use of immunotherapy 2.
Like hormones and neurotransmitters, cytokines 
are a category of signalling molecules; they are used 
extensively in cellular communication. They can be 
proteins, peptides, or glycoproteins. Historically, CYTOKINE THERAPY FOR RCC
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of the central nervous system tended not to respond to 
interferon, and soft-tissue disease tended to respond 
more readily than did metastases to bone.
A recent systematic review by the Cancer Care 
Ontario Program in Evidence-Based Care [c c o -p e b c  
(Canil C, Hotte S. Interferon-alfa in the treatment of 
patients with inoperable locally advanced or meta-
static renal cell cancer, a clinical practice guideline. 
In preparation)] included eight randomized control 
trials 8–16 that directly evaluated the use of i n f α in 
locally advanced or metastatic r c c. These trials 
compared i n f α alone or in combination with other 
agents against control therapies considered to have 
little or no activity in r c c . The overall hazard ratio 
(h r ) for death was 0.79, indicating a 21% reduction 
in the risk of death for patients treated with i n f α. 
The odds of objective response for patients receiving 
i n f α-containing regimens (4.4%–20%) were almost 
7 times those for patients in control groups (0%–3%). 
Overall, toxicity appeared to be worse with i n f α than 
with non-i n f α therapy. The most common adverse 
events after 12 weeks of treatment with i n f α were 
anorexia, fatigue, dry mouth, and rigors. No toxic 
deaths were reported.
Doses and modality of administration of i n f α 
varied across the trials. It is unclear whether i n f α 
has a dose–response effect; however, it is likely 
that toxicity depends on dose and schedule. In view 
of this understanding, it was the consensus of the 
authors of the review that use of the dose and sched-
ule from the largest r c t  showing benefit is reason-
able 8,9. That trial gave an initial subcutaneous dose 
of 5×106 IU, followed by 10×106 IU subcutaneously 
on a thrice-weekly schedule for a total of 12 weeks 
unless disease progresses or an objective response is 
obtained. Treatment may be continued after 12 weeks 
in responding patients.
2.2  Interferon After Cytoreductive Surgery
The c c o -p e b c  performed a meta-analysis of two 
randomized controlled trials comparing cytoreduc-
tive nephrectomy and i n f α2b with i n f α2b alone in 
patients with metastatic r c c  17. Overall survival (o s ) 
and response were assessed. The i n f α2b was initiated 
within 1 month of nephrectomy, was escalated to a 
subcutaneous dose of 5×106 IU/m2 thrice weekly, and 
was continued until disease progression or comple-
tion of 52 weeks of therapy. In both trials, responses 
to i n f α2b were not significantly different between 
the trial arms. The pooled response rates were 6.9% 
for nephrectomy with i n f α2b and 5.7% for i n f α2b 
alone (p = 0.60). The pooled median survival time 
for patients treated with nephrectomy and i n f α2b was 
13.6 months as compared with 7.8 months for patients 
treated with i n f α2b alone (p = 0.002). Nephrectomy 
was associated with a 31% lower risk of death (pooled 
h r : 0.69; 95% c i : 0.55 to 0.87). A survival advantage 
was maintained across all 3 stratification variables, 
which included performance status, site of metastases, 
and disease measurability. However, the magnitude of 
benefit seemed to greater for patients with a perform-
ance status of 0 as compared with 1 (28% vs. 22%), 
non-measurable as compared with measurable disease 
(51% vs. 25%), and lung-only as compared with not 
lung-only metastatic disease (37% vs. 30%). Com-
bined therapy with nephrectomy and i n f α2b was well 
tolerated by most patients. Overall, the data support 
the recommendation that nephrectomy be considered 
in all patients fit enough to undergo the procedure.
2.3  Interleukin-2
The antitumour activity of the il-2 T-cell growth 
factor protein is not completely understood, but is 
believed to occur at least in part by direct activation 
of lymphoid cells. The il-2 affects proliferation and 
maturation of effector cells, enhancing the function 
of natural killer T cells, generating lymphokine-
activated killer cells, and stimulating T-cell and 
B-cell growth, resulting in a reduction in tumour 
growth. The il-2 has no direct antitumour activity 18. 
Administration of il-2 can use any of three routes: 
high-dose il-2 bolus, continuous intravenous infu-
sion, or subcutaneous injection.
A recent systematic review conducted by Hotte 
et al. 19 included r c t s or meta-analyses of r c t s com-
paring treatments with il-2 against regimens without 
il-2 in patients with unresectable or metastatic r c c  
and reporting data on at least one of the following 
outcomes: survival [o s  or progression-free survival 
(p f s), or time to progression], response rates, toxicity, 
or quality of life. The review excluded r c t s that 
compared il-2 with surgery or radiotherapy. Six r c t s 
were included in the review. Across these trials, 1098 
eligible patients were randomized. None of the trials 
was placebo-controlled. All of the trials assessed 
il-2 in combination with other agents, and two of 
the three-arm trials also included a single-agent il-2 
arm. Four trials evaluated subcutaneous il-2, and two 
trials evaluated intravenous administration at a dose 
of 18×106 IU/m2.
In the five trials that reported objective response 
rates, the overall weighted objective response rates for 
il-2–based regimens as compared with regimens that 
were not based on il-2 were 13.3% (range: 9%–39%) 
and 5.3% (range: 0%–20%; p ≤ 0.001) respectively. 
Pooled analysis of 1-year mortality data showed no 
statistically significant difference between il-2–based 
regimens and non–il-2 controls (risk ratio: 0.94; 95% 
c i : 0.67 to 1.30; p = 0.69).
A Cochrane systematic review 5,6 also reviewed 
il-2 with a range of other immunotherapies. Results 
from that meta-analysis also showed no differences 
between il-2 regimens and non–il-2 regimens in both 
1-year mortality and remission rates.
Overall, il-2–containing regimens appeared more 
toxic than did non–il-2 regimens, but the side effects KONERU and HOTTE
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were described as moderately- to well-tolerated by 
most patients in most of the trials. The most common 
grades 3 and 4 toxicities associated with il-2–based 
treatment were fever, chills, malaise, anorexia, oligu-
ria, nausea or vomiting (or both), diarrhea, skin rash 
or allergies, hypotension, pulmonary distress, and 
central nervous system and cardiac toxicity.
2.4  High-Dose Interleukin-2
High-dose il-2 has been defined as il-2 administered 
as an intravenous bolus of at least 600,000 IU/kg every 
8 hours, or a dose exceeding 65×106 IU/m2 daily.
The review by Hotte et al. and the Cochrane re-
view 5,6,19 did not identify any randomized phase iii 
trials comparing high-dose intravenous il-2 with a 
non–il-2 control or placebo; thus the true clinical 
effectiveness of the treatment remains unclear. For 
this reason, it is impossible to recommend use of 
high-dose intravenous il-2 outside of clinical trials 
or investigative settings.
A published series by Fisher and colleagues 
combining data from seven nonrandomized single-
arm phase ii trials suggests that approximately 9% 
of patients can experience complete and long-lasting 
remissions with high-dose il-2. The lack of control 
subjects makes interpretation of these data difficult. 
Proper patient selection is important given the toxicity 
associated with high-dose il-2 therapy, and some at-
tempts have been made with some success to identify 
tissue markers that predict for better response. Atkins 
et al. 20 found that expression levels of carbonic an-
hydrase ix (c a i x ) in tumour correlate with response. 
Survival was also significantly longer in patients 
whose tumour specimens stained highly for c a i x  rela-
tive to patients whose tumour specimens expressed 
low levels of c a i x . Survival for more than 5 years 
was seen only in patients whose tumour specimens 
highly expressed c a i x .
2.5  Combination Regimens of Interferon and 
Interleukin-2
The Cochrane systematic review 5,6 included two 
trials comparing il-2 plus i n f α with i n f α alone. In 
both of those trials, il-2 combined with i n f α was as-
sociated with a statistically significant improvement 
in response rates as compared with i n f α alone, but 
that response did not translate into an improvement 
in survival at 1 year.
In a trial by Atzpodien and colleagues 21, median 
survival was longer for patients treated with a com-
bination of il-2 and i n f α than with either 5-fluorouacil 
[5-f u (25 months; p = 0.04)] or 13-cis-retinoic acid 
(27 months; p = 0.02) than for patients treated with a 
combination of i n f α2a and vinblastine (16 months). 
In an earlier trial by the same group 22, a statistically 
significantly longer median survival was observed 
with il-2 combined with i n f α and 5-f u than with 
tamoxifen (24 months vs. 13 months; p = 0.03). 
Furthermore, median p f s at 1 year was significantly 
longer for patients treated with il-2 combined with 
i n f α2a (20 months) than for patients treated with 
single-agent il-2 (15 months; p = 0.01) or single-agent 
i n f α2a (12 months; p = 0.01).
2.6  Interferon Compared with Interleukin-2
The Cochrane systematic review 5,6 also analyzed 
trials comparing il-2–based regimens with i n f α alone. 
The il-2–based immunotherapies were not observed 
to be superior to i n f α, but il-2–containing regimens 
were associated with greater toxicity.
2.7  Interferon Combined with Inhibitors of 
Angiogenesis
Many of the new anti-angiogenic agents being studied 
in patients with r c c  have been compared with i n f s, 
either i n f  as a single agent or the anti-angiogenic in 
combination with i n f . Given that studies evaluating 
anti-angiogenic agents alone in comparison with i n f  
alone are being reviewed elsewhere in this issue of 
Current Oncology, we concentrate here on studies com-
bining i n f  and an anti-angiogenic agent.
2.7.1  Bevacizumab
In two large r c t s 23,24, the combination of bevacizumab 
and i n f  was associated with significantly longer p f s 
than was i n f α alone. Pooling the p f s data from the 
two trials in a meta-analysis produced a h r  of 0.68 
(95% c i : 0.60 to 0.76; p < 0.00001), which represents 
a 32% reduction in the risk of progression or death 
with combination therapy. Combination therapy was 
associated with more grades 3 and 4 adverse events 
and treatment discontinuations, but in both treatment 
arms, the most frequently reported grade 3 or 4 ef-
fects were i n f α-associated toxicity. Deaths resulting 
from adverse effects were reported with combination 
(n = 8) and with control (n = 7) therapy, and three of 
those deaths were possibly attributable to treatment 
with bevacizumab. Notably, no r c t  of bevacizumab as 
a single agent has yet to be reported, and bevacizumab 
should therefore be used in combination only with i n f  
at the present time.
2.7.2  Temsirolimus
One large trial 25 of temsirolimus that included only 
poor-risk r c c  patients compared temsirolimus alone 
with temsirolimus plus i n f α and with i n f α alone. 
The authors reported longer o s  with single-agent 
temsirolimus than with single-agent i n f α (median: 
10.9 months vs. 7.3 months; h r : 0.73; 95% c i : 
0.58 to 0.92; p = 0.008). No survival benefit was ob-
served in patients treated with the combination of 
temsirolimus and i n f α, but toxicity was increased. 
Median p f s was also longer in patients treated with 
temsirolimus, either alone or in combination with CYTOKINE THERAPY FOR RCC
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i n f α. Temsirolimus-based regimens were associated 
with significantly more grades 3 and 4 anemia, neu-
tropenia, and thrombocytopenia; however, in general, 
temsirolimus alone was better tolerated than was any 
treatment arm that contained i n f α.
2.7.3  Thalidomide
One trial 26 (n = 342) compared the combination of 
thalidomide and i n f α with i n f α alone. No difference 
in os was observed and a 1-month improvement in 
p f s was seen with combination treatment (3.8 months 
vs. 2.8 months; p = 0.04). Based on these modest 
improvements and the considerable toxicity of thal-
idomide, this treatment should not be routinely used 
in patients with r c c .
3.  CONCLUSIONS
For patients with inoperable locally advanced or 
metastatic r c c , results from recent r c t s indicate that 
anti-angiogenic agents are superior to i n f α alone and 
are therefore recommended as the preferred treatment 
option as single agents or in combination with i n f . 
In circumstances in which targeted therapies cannot 
be used, single-agent i n f α may still occasionally be 
used as a treatment option, given that it has been 
shown to improve survival and disease control. The 
benefits of combined immunotherapy (with or with-
out chemotherapy) over i n f α alone are unclear, and 
such combinations should therefore be used only in 
the context of clinical trials. Common side effects of 
i n f α include anorexia, fatigue, nausea and vomiting, 
dry mouth, shivering, and mood changes. The data 
are still insufficient to support the routine use of high-
dose intravenous il-2 therapy outside of a clinical 
trial, and the toxicity of this treatment warrants its 
administration in specialized centers.
Although cytoreductive therapy has been 
evaluated in combination with i n f therapy and has 
been associated with improved survival, its role in 
combination with anti-angiogenic agents remains 
to be established.
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